FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2552022124> ?p ?o ?g. }

• W2552022124 abstract "Introduction Limited real world data are available regarding the effects of adalimumab (ADA) on UK patients with moderate to severe ulcerative colitis (UC). Methods INSPIRADA was a single-arm, multi-country, open-label study that evaluated the effect of ADA on patients with UC treated according to usual clinical practice. Adults with active moderate to severe UC who failed immunosuppressive therapies and experienced rectal bleeding within 7 days of baseline (BL) were enrolled. Prior use of anti-TNF was allowed. Clinical outcomes included Simple Clinical Colitis Activity Index (SCCAI) response (a decrease ≥2 points compared to BL) and remission (SCCAI ≤2). HRQoL (EQ-5D-5L and SIBDQ), treatment satisfaction with medication (TSQM), and work productivity and activity impairment (WPAI) were measured from BL to week 26. Direct medical costs (excluding ADA costs) were estimated using 2014 UK National Health Service reference costs. Indirect costs were based on the WPAI using average weekly earnings from the 2014 UK Annual Salary Survey of Hours and Earnings. Change (defined as 6 mo after start of ADA vs 6 mo before) in resource use and costs were calculated. Data for the intent-to-treat population in UK were analysed. Missing data were imputed using last observation carried forward. Results Data from 90 UK patients (58% male, mean age 39 yrs) were analysed. Mean SCCAI at BL was 8.2. At week 2, 74% achieved SCCAI response and 21% achieved SCCAI remission. At week 8, 73% achieved SCCAI response, 40% in remission and 49% had no blood in stool. At week 26, 66% achieved SCCAI response, 42% in remission and 51% had no blood in stool. Significant improvements, as early as within 2 weeks, in SIBDQ (19.5 points, p Conclusion Real world rates of response, remission and improvements in HRQoL with ADA for UK patients with moderate to severe UC were clinically meaningful. ADA improved work productivity, increased patient satisfaction with therapy and reduced health care associated costs for these patients in the UK. Disclosure of Interest P. Irving Grant/research support from: AbbVie; Falk; Ferring; Genentech/Roche; Hospira; Merck; Pharmacosmos; Shire; Takeda; Tillotts; Topivert; Vifor and Warner Chilcott, Conflict with: Advisor/invited lecturer for: AbbVie; Falk; Ferring; Genentech/Roche; Hospira; Merck; Pharmacosmos; Shire; Takeda; Tillotts; Topivert; Vifor and Warner Chilcott, F. Cummings Conflict with: Advisor/lectures for: Takeda, Abbvie, MSD, Biogen, Napp, Hospira, Janssen, S. Bloom Conflict with: Advisor/lectures for: Takeda, Tillotts, Abbvie, MSD, Pharmacosmos, Vifor, Johnson and Johnson, A. Lazar Shareholder of: AbbVie, Employee of: AbbVie, A. Robinson Shareholder of: AbbVie, Employee of: AbbVie, B. Pappalardo Shareholder of: AbbVie, Employee of: AbbVie, M. Bereswill Shareholder of: AbbVie, Employee of: AbbVie, M. Skup Shareholder of: AbbVie, Employee of: AbbVie, N. Chen Shareholder of: AbbVie, Employee of: AbbVie, T. Finney-Hayward Shareholder of: AbbVie, Employee of: AbbVie, S. Wang Shareholder of: AbbVie, Employee of: AbbVie, R. Thakkar Shareholder of: AbbVie, Employee of: AbbVie, S. Travis Grant/research support from: AbbVie; Asahi; Boehringer Ingelheim; BMS; Cosmo; Elan; Ferring; FPRT Bio; Genentech/Roche; Genzyme; Glenmark; GW Pharmaceuticals; Lilly; Merck; Novartis; Novo Nordisk; Ocera; Pfizer; Shire; Santarus; SigmoidPharma; Synthon; Takeda; Tillotts; Topivert; Trino Therapeutics with Wellcome Trust; UCB Pharma; Vertex; VHsquared; Vifor; Warner Chilcott and Zeria, Conflict with: Advisor or paid instructor for: AbbVie; Asahi; Boehringer Ingelheim; BMS; Cosmo; Elan; Ferring; FPRT Bio; Genentech/Roche; Genzyme; Glenmark; GW Pharmaceuticals; Lilly; Merck; Novartis; Novo Nordisk; Ocera; Pfizer; Shire; Santarus; SigmoidPharma; Synthon; Takeda; Tillotts; Topivert; Trino Therapeutics with Wellcome Trust; UCB Pharma; Vertex; VHsquared; Vifor; Warner Chilcott and Zeria. All advisory boards were suspended Q1 2012–14 while President of ECCO" @default.
• W2552022124 created "2016-11-30" @default.
• W2552022124 creator A5005948755 @default.
• W2552022124 creator A5014242797 @default.
• W2552022124 creator A5036380749 @default.
• W2552022124 creator A5036732347 @default.
• W2552022124 creator A5037685574 @default.
• W2552022124 creator A5039972019 @default.
• W2552022124 creator A5041744931 @default.
• W2552022124 creator A5054688598 @default.
• W2552022124 creator A5056966450 @default.
• W2552022124 creator A5067805030 @default.
• W2552022124 creator A5075962668 @default.
• W2552022124 creator A5079729596 @default.
• W2552022124 creator A5084209893 @default.
• W2552022124 date "2016-06-01" @default.
• W2552022124 modified "2023-09-25" @default.
• W2552022124 title "PTU-069 Effect of Adalimumab on Patients with Moderate to Severe Ulcerative Colitis in UK Clinical Practice Setting: Results from Inspirada" @default.
• W2552022124 doi "https://doi.org/10.1136/gutjnl-2016-312388.154" @default.
• W2552022124 hasPublicationYear "2016" @default.
• W2552022124 type Work @default.
• W2552022124 sameAs 2552022124 @default.
• W2552022124 citedByCount "0" @default.
• W2552022124 crossrefType "journal-article" @default.
• W2552022124 hasAuthorship W2552022124A5005948755 @default.
• W2552022124 hasAuthorship W2552022124A5014242797 @default.
• W2552022124 hasAuthorship W2552022124A5036380749 @default.
• W2552022124 hasAuthorship W2552022124A5036732347 @default.
• W2552022124 hasAuthorship W2552022124A5037685574 @default.
• W2552022124 hasAuthorship W2552022124A5039972019 @default.
• W2552022124 hasAuthorship W2552022124A5041744931 @default.
• W2552022124 hasAuthorship W2552022124A5054688598 @default.
• W2552022124 hasAuthorship W2552022124A5056966450 @default.
• W2552022124 hasAuthorship W2552022124A5067805030 @default.
• W2552022124 hasAuthorship W2552022124A5075962668 @default.
• W2552022124 hasAuthorship W2552022124A5079729596 @default.
• W2552022124 hasAuthorship W2552022124A5084209893 @default.
• W2552022124 hasConcept C126322002 @default.
• W2552022124 hasConcept C2776207728 @default.
• W2552022124 hasConcept C2777575956 @default.
• W2552022124 hasConcept C2778886723 @default.
• W2552022124 hasConcept C2779134260 @default.
• W2552022124 hasConcept C2780132546 @default.
• W2552022124 hasConcept C2780479503 @default.
• W2552022124 hasConcept C2908647359 @default.
• W2552022124 hasConcept C71924100 @default.
• W2552022124 hasConcept C99454951 @default.
• W2552022124 hasConceptScore W2552022124C126322002 @default.
• W2552022124 hasConceptScore W2552022124C2776207728 @default.
• W2552022124 hasConceptScore W2552022124C2777575956 @default.
• W2552022124 hasConceptScore W2552022124C2778886723 @default.
• W2552022124 hasConceptScore W2552022124C2779134260 @default.
• W2552022124 hasConceptScore W2552022124C2780132546 @default.
• W2552022124 hasConceptScore W2552022124C2780479503 @default.
• W2552022124 hasConceptScore W2552022124C2908647359 @default.
• W2552022124 hasConceptScore W2552022124C71924100 @default.
• W2552022124 hasConceptScore W2552022124C99454951 @default.
• W2552022124 hasLocation W25520221241 @default.
• W2552022124 hasOpenAccess W2552022124 @default.
• W2552022124 hasPrimaryLocation W25520221241 @default.
• W2552022124 hasRelatedWork W2009656202 @default.
• W2552022124 hasRelatedWork W2315815725 @default.
• W2552022124 hasRelatedWork W2328190078 @default.
• W2552022124 hasRelatedWork W2332601515 @default.
• W2552022124 hasRelatedWork W2411374214 @default.
• W2552022124 hasRelatedWork W2755475719 @default.
• W2552022124 hasRelatedWork W2892791765 @default.
• W2552022124 hasRelatedWork W2909951148 @default.
• W2552022124 hasRelatedWork W2947887453 @default.
• W2552022124 hasRelatedWork W2949868377 @default.
• W2552022124 hasRelatedWork W2952720162 @default.
• W2552022124 hasRelatedWork W3081287169 @default.
• W2552022124 hasRelatedWork W3164306653 @default.
• W2552022124 hasRelatedWork W3164541101 @default.
• W2552022124 hasRelatedWork W3164748695 @default.
• W2552022124 hasRelatedWork W3165123004 @default.
• W2552022124 hasRelatedWork W3165346755 @default.
• W2552022124 hasRelatedWork W3165615730 @default.
• W2552022124 hasRelatedWork W3165823523 @default.
• W2552022124 hasRelatedWork W3200728010 @default.
• W2552022124 isParatext "false" @default.
• W2552022124 isRetracted "false" @default.
• W2552022124 magId "2552022124" @default.
• W2552022124 workType "article" @default.